scispace - formally typeset
E

Erin Boland

Researcher at University of North Carolina at Chapel Hill

Publications -  17
Citations -  750

Erin Boland is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Randomized controlled trial & Latent tuberculosis. The author has an hindex of 9, co-authored 17 publications receiving 494 citations. Previous affiliations of Erin Boland include Research Triangle Park.

Papers
More filters
Journal ArticleDOI

Defining treatment-resistant depression.

TL;DR: Translating research findings or systematic reviews into clinical practice guidelines challenging and inconsistent in treatment‐resistant depression is challenged and inconsistent.
Journal ArticleDOI

Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for the US Preventive Services Task Force.

TL;DR: Hormone therapy for the primary prevention of chronic conditions in menopausal women is associated with some beneficial effects but also with a substantial increase of risks for harms, and available evidence regarding benefits and harms of early initiation of hormone therapy is inconclusive.
Journal ArticleDOI

Comparative Benefits and Harms of Antidepressant, Psychological, Complementary, and Exercise Treatments for Major Depression: An Evidence Report for a Clinical Practice Guideline From the American College of Physicians.

TL;DR: A systematic review funded by the Agency for Healthcare Research and Quality that focused on 2 key issues, how effective are second-generation antidepressants compared with alternative pharmacologic and nonpharmacologic interventions as an initial treatment choice and for patients who do not achieve remission with a second- Generation antidepressant, what is the comparative effectiveness of augmentation of the original drug or switching to another treatment?
Journal Article

Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults

TL;DR: Treatment reduced the risk of active TB among the populations included in this review, and both the TST and IGRAs are moderately sensitive and highly specific within countries with low TB burden.